Analysts Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) PT at $54.94

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have received a consensus rating of “Moderate Buy” from the eighteen research firms that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $54.94.

A number of research firms recently weighed in on NTLA. Stifel Nicolaus lowered their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a report on Wednesday, September 11th. Chardan Capital raised their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a report on Monday, November 18th. Royal Bank of Canada reiterated an “outperform” rating and set a $54.00 price target on shares of Intellia Therapeutics in a report on Thursday, September 19th. Oppenheimer lowered their price target on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Finally, StockNews.com raised shares of Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th.

Intellia Therapeutics Stock Down 4.9 %

Shares of NASDAQ:NTLA opened at $12.90 on Wednesday. Intellia Therapeutics has a twelve month low of $12.47 and a twelve month high of $34.87. The stock’s 50 day moving average is $16.13 and its 200-day moving average is $20.60. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of -2.37 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same quarter last year, the firm posted ($1.38) EPS. The business’s revenue for the quarter was down 24.1% compared to the same quarter last year. Equities research analysts anticipate that Intellia Therapeutics will post -5.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intellia Therapeutics news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at $893,698.12. This represents a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Blue Trust Inc. raised its holdings in Intellia Therapeutics by 1,664.3% during the 2nd quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock valued at $33,000 after acquiring an additional 1,398 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after buying an additional 1,550 shares in the last quarter. Eastern Bank bought a new stake in shares of Intellia Therapeutics during the third quarter valued at about $41,000. First Horizon Advisors Inc. lifted its holdings in shares of Intellia Therapeutics by 22.1% in the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after buying an additional 472 shares in the last quarter. Finally, Values First Advisors Inc. bought a new position in shares of Intellia Therapeutics in the third quarter valued at approximately $54,000. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.